Skip to content

99Tc-MDP intrarticular injection for knee osteoarthritis

Clinical study of 99Tc-MDP intrarticular injection for knee osteoarthritis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114977
Enrollment
Unknown
Registered
2025-12-19
Start date
2025-12-30
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary knee osteoarthritis with pain

Interventions

99Tc-MDPknee joint cavity injection group:99Tc MDP 2.5mg, 2ml knee joint cavity injection treatment, qwX3-5 times.

Sponsors

Shanghai Tenth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for osteoarthritis and the following diagnostic criteria for mild to moderate knee osteoarthritis in the 2024 edition of Chinese Guidelines for the Diagnosis and Treatment of Osteoarthritis; 2. The course of disease is longer than 1 month; 3. Over 45 years of age; 4. Accompanied by knee pain; 5. Bone scan showed concentration of radioactivity in knee joint; 6. Male and female.

Exclusion criteria

Exclusion criteria: 1. Had knee replacement; 2. Inflammatory knee arthritis or joint infection; 3. Neuropathic arthropathy; 4. Reactive arthritis; 5. periarticular fracture; 6. Gouty knee arthritis; 7. Liver and kidney dysfunction; 8. Traumatic arthritis; 9. Serious heart and lung diseases and blood diseases; 10. Obvious knee internal and external inversion deformity or vascular nerve injury of the affected limb; 11. No nonsteroidal anti-inflammatory drugs or other drugs to improve joint function were used in the 1 month before inclusion (except for occasional internal administration of traditional Chinese medicine prescriptions and external plaster); 12. Skin rupture and infection at the puncture site; 13. Patients with severe coagulation dysfunction and anaesthetic allergy.

Design outcomes

Primary

MeasureTime frame
Lequesne score;VAS score;

Secondary

MeasureTime frame
quality of life;Joint function;

Countries

China

Contacts

Public ContactChao Ma

Shanghai Tenth People's Hospital

ponymachao@163.com+86 18721288964

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026